Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relationship Between the Residual Plasma Concentration of Sorafenib and the Occurrence of Adverse Events in Patients Treated for Hepatocellular Carcinoma

NCT03340636 is registered in ClinicalTrials.gov with University Hospital, Caen as lead sponsor.

NCT NCT03340636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03340636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relationship Between the Residual Plasma Concentration of Sorafenib and the Occurrence of Adverse Events in Patients Treated for Hepatocellular Carcinoma
Lead sponsor
University Hospital, Caen
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2018
Completion date
March 31, 2019
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic hepatocellular carcinoma